Neuromuscular

The PDUFA date for SRP-9001, developed in partnership between Sarepta and Roche, is set for May 29, 2023. The BLA was submitted for accelerated approval.

The division chief of stroke and vascular neurology at Duke Health provided perspective on the multidisciplinary team needed to treat neuromuscular poststroke symptoms, as well as exciting innovations on the horizon. [WATCH TIME: 4 minutes]

The president of the International Neuropalliative Care Society detailed potential disease states that could benefit from neuropalliative care as well as the importance of the patient community in expanding this type of approach. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

Neurology News Network for the week ending November 26, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 25, 2022.

The codirector of the ALS Center at Washington University School of Medicine detailed the reasons for hope within the ALS space and the promising innovations in the coming future. [WATCH TIME: 4 minutes]

The president of the International Neuropalliative Care Society provided perspective on the growth of the field of neuropalliative care, the organization’s role, and how clinicians are overcoming current barriers in place.

The president of the International Neuropalliative Care Society discussed the area in which neuropalliative has expanded and improved, as well as the potential in the coming years. [WATCH TIME: 2 minutes]

The president of the International Neuropalliative Care Society provided an overview of the organization’s recently concluded conference and the significance of the growth of neuropalliative care. [WATCH TIME: 6 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

Neurology News Network for the week ending November 19, 2022. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 18, 2022.

Compared with placebo, a greater proportion of patients on rituximab met the primary end point of minimal disease manifestations at 16 weeks, and demonstrated favorable results on several secondary end points.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with George Small, MD. [LISTEN TIME: 33 minutes]

The division chief of stroke and vascular neurology at Duke Health discussed advantages and capabilities, as well as limitations and barriers of transcranial direct current stimulation to treat poststroke symptoms. [WATCH TIME: 4 minutes]

The codirector of the ALS Center at Washington University School of Medicine in St. Louis provided perspective on the phase 3 VALOR findings of tofersen, an antisense agent currently under review to treat SOD1-mutated ALS.

Zilucoplan, a complement C5 inhibitor, demonstrated a safe and tolerable profile, while meeting its primary and secondary end points in the phase 3 RAISE trial—the basis for its new drug application.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

Jennifer Roggenbuck, MS, LGC, an associate professor of neurology and internal medicine at The Ohio State University Wexner Medical Center, discussed her presentation on evidence-based consensus guidelines for genetic testing and counseling from the 2022 NEALS Consortium.

Neurology News Network for the week ending November 12, 2022. [WATCH TIME: 4 minutes]

James Wymer, MD, FAAN, discussed his presentation at the 2022 Annual NEALS meeting on improving speech and swallowing using Neudexta for patients with ALS.